12 citations
,
January 2016 in “Journal of clinical biochemistry and nutrition” In this study, combining deferasirox with sorafenib significantly reduced liver fibrosis and preneoplastic lesions in rats while also lessening adverse effects compared to sorafenib alone.
March 2025 in “Journal of Clinical Medicine” This study highlighted the potential of iron chelators, deferoxamine and deferiprone, to improve hair density, thickness, and elasticity and reduce hair loss by up to 66.8% over six months in individuals with autoimmune alopecia, suggesting they may offer a promising therapeutic option.
9 citations
,
February 2019 in “BMC cancer” This study found that M30 may protect against cyclophosphamide-induced alopecia in mice by enhancing hair growth and preventing abnormal hair, suggesting its potential as a treatment.
October 2006 in “Clinical Cancer Research” This study found that doxorubicin-induced oxidative stress downregulates FLIPs and phosphorylates EF2, sensitizing prostate cancer cells to TRAIL; antioxidants may reduce doxorubicin's effectiveness, warranting further investigation.
October 2025 in “Journal of Investigative Dermatology” This review highlights the critical role of iron in skin functions and suggests potential dermatologic therapies targeting the iron-skin axis.